[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349169-105":59,"doc-detail-349169-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cancer-incidence-among-users-of-glucagon-like-peptide-1-receptor-agonists","Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists","","Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are novel antidiabetic drugs whose relationship to cancer risk remains unsettled. This retrospective cohort study evaluates common cancer incidence after GLP-1RA initiation by comparing outcomes with insulin among patients diagnosed with type 2 diabetes between 2013–2021. Using IBM-MarketScan data, overlap propensity score weighting and Cox models were applied to estimate risk. Among 106,088 patients, cancer developed in 1.9%, with lower liver and pancreatic cancer risk for GLP-1RAs and no increased risk for other major cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-incidence-among-users-of-glucagon-like-peptide-1-receptor-agonists/349169/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-incidence-among-users-of-glucagon-like-peptide-1-receptor-agonists/349169.png","ImageObject",300,407,{"name":92,"@type":93},"Terk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study designed to investigate?","Question",{"text":112,"@type":113},"The study investigated the risk of common cancers following GLP-1RA initiation among patients with type 2 diabetes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients selected and which data source was used?",{"text":117,"@type":113},"Patients with type 2 diabetes diagnosed between 2013 and 2021 were identified using the IBM-MarketScan database, then categorized into GLP-1RA exposure and insulin comparison groups.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings on cancer risk?",{"text":121,"@type":113},"Compared with insulin, GLP-1RA use was associated with a significantly lower risk of liver cancer and pancreatic cancer, while the risk of other major cancers remained comparable.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349169,1790486573,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Cancer Incidence Among Users of Glucagon‑Like Peptide‑1 Receptor Agonists  \nZayed Rashid, MD3 , Selamawit Woldesenbet, PhD 1 , Mujtaba Khalil, MD 1 , Abdullah Altaf, MD 1 , Shahzaib Zindani, MD1, Areesh Mevawalla, MD1, Azza Sarfraz, MD1, Khalid Mumtaz, MBBS, MSc2, and Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA 1  \n1Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA; 2Department of Internal Medicine, Division of Gastroenterology, Hepatology & Nutrition, College of Medicine, The Ohio State University, Columbus, OH, USA; 3Department of Internal Medicine, Conemaugh Memorial Medical Center, Johnstown, PA, USA  \nABSTRACT  \nBACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are novel antidiabetic agents that may influence cancer risk. While some studies suggest protective effects, others raise concerns about potential oncogenic associations.  \nOBJECTIVE: To investigate the risk of common cancers with GLP-1RA initiation.  \nDESIGN: Retrospective cohort study.  \nPARTICIPANTS AND MAIN MEASURES: Patients diagnosed with type 2 diabetes between 2013–2021 were identified using IBM-MarketScan database and were categorized into exposure (i.e . , GLP-1RA) and comparison (i.e. , insulin) groups. Overlap Propensity Score Weighting (OPSW), followed by Cox proportional hazards models, was used to assess cancer risk.  \nKEY RESULTS: Among 106,088 patients, most were male ( n = 44,059, 51.3%), and the mean age was 51 (SD: ± 9.8) years; 50.8%( n = 53,924) of patients had GLP-1RA initiation. Overall, 1.9%( n = 1,594) ofthe individuals developed cancer (thyroid: n = 110, 0.1%; lung: n = 127, 0.1%; breast: n = 369, 0.4%; esophagus: n = 20, 0.02%; gastric: n = 34, 0.03%; liver: n = 116, 0.1%; biliary: n = 20, 0.02%; pancreatic: n = 87, 0.1%; small intestine: n = 23, 0.02%; renal: n = 128, 0. 1%; bladder: n = 66, 0.1%; colorectal: n = 175, 0.2%; prostate: n = 322, 0.4%; ovarian: n = 51, 0. 1%; endometrial: n = 130, 0.2%; neuroendocrine: n = 60, 0.1%) . Compared to insulin, GLP- 1RA medications were associated with a significantly lower risk of liver cancer (HR: 0.47, 95% CI: 0.27–0.82) and pancreatic cancer (HR: 0.23, 95% CI: 0.11–0.51) . Risk of all other cancers remained comparable between the two groups (all p >0.05) .  \nCONCLUSIONS: GLP-1RA use was associated with a lower incidence of liver and pancreatic cancer, with no increased risk observed for other major cancers. As these medications become more widely used, further research is warranted to better define their long-term cancer-related safety profile.  \nKEYWORDS: GLP-1RA medications; hepatocellular carcinoma; thyroid cancer; pancreas cancer; diabetes; obesity  \nReceived October 29, 2025  \nAccepted February 12, 2026  \nPublished online February 26, 2026  \nJ Gen Intern Med 41(7):1771–9  \nDOI: 10. 1007/s11606-026-10300-1 © The Author(s) 2026  \nINTRODUCTION  \nCancer is the second leading cause of death in the United States with an estimated increase of over half a million cancer-related deaths annually. 1 The pathogenesis of most cancer types may differ, but several common modifiable risk factors can be addressed to help prevent many forms of cancer.2 These modifiable factors can be environmental (e.g. , toxic exposures), behavioral (e.g. , alcohol intake), or metabolic (e. g. , obesity or diabetes) .2 Recently, there has been growing emphasis on the investigation of modern therapeutics that can impact cancer incidence either through direct mechanisms or by targeting indirect pathways.3 ,4 One such modern class of medications is glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which were originally approved to manage diabetes and later found to offer additional benefits for obesity and metabolic disorders such as steatohepatitis.5 ,6  \nGLP-1RA medications primarily work by mimicking endogenous incretins that help regulate key metabolic pathways such as β-oxidation of fatty acids and glycogenolysis by influenc","cbCairX65YU1a3cH","https://ap.wps.com/l/cbCairX65YU1a3cH","pdf",1439430,"English","# Abstract\n## Background and objective\n## Design and methods\n## Key results and conclusions\n# Introduction\n# Materials and Methods\n## Database","[{\"question\":\"What was the study designed to investigate?\",\"answer\":\"The study investigated the risk of common cancers following GLP-1RA initiation among patients with type 2 diabetes.\"},{\"question\":\"How were patients selected and which data source was used?\",\"answer\":\"Patients with type 2 diabetes diagnosed between 2013 and 2021 were identified using the IBM-MarketScan database, then categorized into GLP-1RA exposure and insulin comparison groups.\"},{\"question\":\"What were the main findings on cancer risk?\",\"answer\":\"Compared with insulin, GLP-1RA use was associated with a significantly lower risk of liver cancer and pancreatic cancer, while the risk of other major cancers remained comparable.\"}]","Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists | PDF",1790082040,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/621dc069b9c29ca3fcab9892bfd9ab37.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a8e09ea23046a525ec5a89915ce5d72.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ecad2de1af991c1e54a4d88994734f5.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d400a972fb08139ac454e89c773a49a1.webp",980,1301]